United States Food and Drug Administration
PulseAugur coverage of United States Food and Drug Administration — every cluster mentioning United States Food and Drug Administration across labs, papers, and developer communities, ranked by signal.
No coverage in the last 90 days.
- subsidiary of United States Department of Health and Human Services 100%
- parent of Center for Drug Evaluation and Research 100%
- employed by Marty Makary 95%
- employed by Kyle Diamantas 90%
- other Marty Makary 60%
- affiliated with Joe Biden Administration cabinet 50%
- other Supreme Court of the United States 50%
4 day(s) with sentiment data
-
Lin Junyan launches AI firm at $2B valuation; FDA approves diabetes drug raw material
Lin Junyan has launched a new company that has achieved a valuation of approximately $2 billion. The company is focused on the emerging field of AI. Separately, Tonghe Pharmaceutical received FDA approval for its Kaglie…
-
Pharma leaders seek stable FDA amid pricing policy concerns
Pharmaceutical industry leaders are advocating for stability and predictability from the next Food and Drug Administration (FDA) commissioner following a period of leadership changes and uncertainty. CEOs from major dru…
-
Digital twins proposed as synthetic controls for clinical trials
Researchers have published a paper detailing the use of digital twins as synthetic control arms in single-arm clinical trials. These advanced machine learning models can generate personalized predictions of disease prog…
-
US Food and Drug Commissioner Marty Makary resigns amid Republican pressure
US Food and Drug Commissioner Marty Makary has resigned following significant pressure from Republican lawmakers and anti-abortion groups. President Donald Trump announced Makary's departure, stating he was "having some…
-
FDA Commissioner Marty Makary resigns after turbulent tenure
FDA Commissioner Dr. Marty Makary is resigning after a turbulent 13-month tenure marked by significant organizational upheaval and controversies. His leadership faced criticism from various groups, including health indu…
-
US debates AI policy, FDA advances AI in clinical trials
The US is experiencing a policy divide regarding artificial intelligence, with the FDA actively promoting AI for clinical trials. Meanwhile, discussions are ongoing about access to frontier AI models, highlighting a bro…
-
Open-source tool grants AI full access to pharma R&D data
An open-source project called drug-pipeline-mcp has been released, offering AI agents comprehensive access to pharmaceutical R&D data. This tool aggregates information on clinical trials, FDA/EMA approvals, safety repor…
-
WHOOP raises $575M at $10.1B valuation, eyes health platform pivot
WHOOP, a company known for its fitness wearables, has secured $575 million in Series G funding at a $10.1 billion valuation. This funding round, which included strategic investments from healthcare giants Abbott and May…
-
FDA Commissioner Marty Makary's Future Uncertain Amidst Political Drama
The Food and Drug Administration (FDA) is experiencing internal turmoil regarding the potential dismissal of Commissioner Marty Makary. Reports indicated Makary was to be fired, but he appears to have been spared, thoug…
-
AI/ML studies surge in high-income countries, focus on neoplasms
A recent analysis of AI/ML studies conducted between 2010 and 2023 reveals a significant growth trend, particularly in high-income nations. Out of 3,106 studies examined, a notable portion were FDA-regulated (7.6%) and …
-
Chinese Markets See Shifting Capital Flows Amidst Sectoral Volatility
Multiple 36Kr news flashes report on daily capital flows in the Chinese stock market, with varying trends in fund inflows and outflows across different sectors. While some reports indicate net inflows into public utilit…
-
Right to Try laws fail to provide patient access to unapproved drugs
The "Right to Try" and FDA's Expanded Access pathways are intended to allow patients with severe illnesses to access unapproved treatments. However, these programs are rarely utilized because biotech companies, which fu…
-
Gates Foundation funds Kanvas Biosciences' AI-driven microbiome pill for malnutrition
Kanvas Biosciences has secured funding from the Bill & Melinda Gates Foundation to develop a novel treatment for environmental enteric dysfunction (EED), a disease affecting millions of children globally. The startup is…
-
Trump administration signals AI safety pivot, eyes China talks
The Trump administration is reportedly considering a significant shift in its approach to AI safety, potentially including executive actions to regulate advanced AI models. This pivot comes as President Trump prepares f…
-
Databricks Genie tool accelerates RWE analysis for medical affairs
Databricks has introduced a new tool called Genie for Medical Affairs Intelligence, designed to address the "RWE Fluency Gap" in the life sciences industry. This tool allows medical affairs leaders to query complex real…
-
DIY electrolysis machine offers permanent hair removal; Amazon Luna adds new games
This cluster contains two unrelated news items. The first discusses a DIY electrolysis machine for permanent hair removal, referencing the FDA's classification of electrolysis as the sole permanent method. The second it…
-
Neuralink develops surgical robot for brain access, aims for universal neural interface
Neuralink is developing a surgical robot designed to access any part of the brain. The company aims to create a universal neural interface to treat brain-related conditions. This device is currently in the research phas…
-
Anthropic CEO warns of AI-driven software bankruptcies, opposes strict regulation
Anthropic CEO Dario Amodei predicts that AI will lead to widespread software bankruptcies as the technology automates many existing coding tasks. He argues against strict, FDA-style regulation for AI, suggesting it coul…
-
FDA launches updated AI data platform; research shows women in AI-vulnerable jobs
The U.S. Food and Drug Administration (FDA) has introduced an updated data platform that incorporates artificial intelligence. Concurrently, new research indicates that women are disproportionately employed in jobs that…
-
Sunscreen's two-hour reapplication rule lacks scientific evidence, analysis finds
The common guideline to reapply sunscreen every two hours while in the sun is not based on strong scientific evidence. This recommendation appears to have originated from a 2007 proposed rule by the FDA, which cited stu…